Skip to main content

Table 2 Summarized risk ratios (RR) with 95% confidence intervals (95% CIs) for adverse events

From: Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries

Adverse events

RR (95% CIs)

P value

Maternal adverse events

 Fatigue

1.03 (0.65, 16.25)

0.586

 Cough

1.42 (0.60, 3.39)

0.983

 Diarrhea

3.61 (0.75, 17.41)

0.424

 Fever

1.56 (0.40, 6.17)

0.110

 Nausea

2.06 (0.19, 22.37)

0.523

 Pruritus

0.41 (0.08, 2.08)

0.552

 Palpitation

0.34 (0.01, 8.33)

0.283

 Dyspepsia

3.09 (0.13, 74.99)

0.511

 Rash

0.95 (0.28, 3.19)

0.488

 Insomnia

3.09 (0.13, 74.99)

0.928

 Dizziness

0.52 (0.05, 5.59)

0.488

 Abdominal pain

3.09 (0.13, 74.98)

0.586

 Upper respiratory infection

0.34 (0.04, 3.25)

0.731

 Gestational diabetes

3.41 (0.15, 79.47)

0.351

 Arrhythmia

3.25 (0.28, 46.72)

0.612

Infant adverse events

 Hypospadias

2.78 (0.12, 67.39)

0.529

 Torticollis

1.85 (0.17, 20.08)

0.612

 Umbilical hernia

2.78 (0.12, 67.39)

0.529

 Pneumonia

4.64 (0.23, 95.24)

0.470

 Bronchitis

0.31 (0.01, 7.49)

0.948

 Birth weight < 2500 g

1.10 (0.07, 16.43)

0.185

 Fetal growth retardation

0.79 (0.15, 21.34)

0.546

 Congenital malformation

2.34 (0.25, 64.7)

0.445